Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2013 4
2014 2
2015 2
2016 1
2017 4
2018 2
2020 3
2021 2
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed for Bookshelf ID: 4859202

20 results

Results by year

Filters applied: . Clear all
Page 1
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buzgau A, Cheng AC, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Lamontagne F, Lawler PR, Leavis HL, Linstrum KM, Litton E, Lorenzi E, Marshall JC, Mayr FB, McAuley DF, McGlothlin A, McGuinness SP, McVerry BJ, Montgomery SK, Morpeth SC, Murthy S, Orr K, Parke RL, Parker JC, Patanwala AE, Pettilä V, Rademaker E, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Sligl WI, Turgeon AF, Turner AM, van de Veerdonk FL, Zarychanski R, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Webb SA, Derde LPG. REMAP-CAP Investigators, et al. N Engl J Med. 2021 Apr 22;384(16):1491-1502. doi: 10.1056/NEJMoa2100433. Epub 2021 Feb 25. N Engl J Med. 2021. PMID: 33631065 Free PMC article. Clinical Trial.
Sarilumab use in severe SARS-CoV-2 pneumonia.
Gremese E, Cingolani A, Bosello SL, Alivernini S, Tolusso B, Perniola S, Landi F, Pompili M, Murri R, Santoliquido A, Garcovich M, Sali M, De Pascale G, Gabrielli M, Biscetti F, Montalto M, Tosoni A, Gambassi G, Rapaccini GL, Iaconelli A, Zileri Del Verme L, Petricca L, Fedele AL, Lizzio MM, Tamburrini E, Natalello G, Gigante L, Bruno D, Verardi L, Taddei E, Calabrese A, Lombardi F, Bernabei R, Cauda R, Franceschi F, Landolfi R, Richeldi L, Sanguinetti M, Fantoni M, Antonelli M, Gasbarrini A; GEMELLI AGAINST COVID-19 Group. Gremese E, et al. EClinicalMedicine. 2020 Oct;27:100553. doi: 10.1016/j.eclinm.2020.100553. Epub 2020 Oct 2. EClinicalMedicine. 2020. PMID: 33043284 Free PMC article.
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
Della-Torre E, Campochiaro C, Cavalli G, De Luca G, Napolitano A, La Marca S, Boffini N, Da Prat V, Di Terlizzi G, Lanzillotta M, Rovere Querini P, Ruggeri A, Landoni G, Tresoldi M, Ciceri F, Zangrillo A, De Cobelli F, Dagna L; SARI-RAF Study Group; SARI-RAF Study Group members. Della-Torre E, et al. Ann Rheum Dis. 2020 Oct;79(10):1277-1285. doi: 10.1136/annrheumdis-2020-218122. Epub 2020 Jul 3. Ann Rheum Dis. 2020. PMID: 32620597 Free PMC article.
Drugs for rheumatoid arthritis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2018 Jul 30;60(1552):123-128. Med Lett Drugs Ther. 2018. PMID: 30044766 No abstract available.
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
Genovese MC, van Adelsberg J, Fan C, Graham NMH, van Hoogstraten H, Parrino J, Mangan EK, Spindler A, Huizinga TWJ, van der Heijde D; EXTEND study investigators. Genovese MC, et al. Rheumatology (Oxford). 2018 Aug 1;57(8):1423-1431. doi: 10.1093/rheumatology/key121. Rheumatology (Oxford). 2018. PMID: 29746672 Free PMC article. Clinical Trial.
Sarilumab (Kevzara) for rheumatoid arthritis.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2017 Aug 14;59(1527):134-136. Med Lett Drugs Ther. 2017. PMID: 28787744 No abstract available.
Sarilumab: First Global Approval.
Scott LJ. Scott LJ. Drugs. 2017 Apr;77(6):705-712. doi: 10.1007/s40265-017-0724-2. Drugs. 2017. PMID: 28290137 Review.
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR. Fleischmann R, et al. Arthritis Rheumatol. 2017 Feb;69(2):277-290. doi: 10.1002/art.39944. Arthritis Rheumatol. 2017. PMID: 27860410 Free PMC article. Clinical Trial.
20 results